A metal-free porphyrin T4PP with pyridine group is proposed as a new electrode for lithium/sodium-based dual-ion batteries (LDIBs/SDIBs). The electrochemical performance and reaction mechanism of T4PP are explored thoroughly. Extended...
Organic cathode materials have recently attracted abundant attention due to their flexible structural tunability and recyclability. However, the low intrinsic electrical conductivity and high solubility in electrolytes of organic electrode materials have significantly limited their practical application. Herein, we present [5,15-bis(ethynyl)-10,20-difurylporphinato] copper(II) (Cu-DEOP) as a new cathode for rechargeable organic lithium batteries (ROLBs). The combination of both ethynyl and furyl groups of the CuDEOP cathode with a nanorod structure renders it with enhanced structural stability and an extended delocalized πelectron system to deliver excellent cycling stability (capacity retention of 76% after 6000 cycles) and a high power density (16 kW kg −1 ). The furyl electroactive groups participate in charge storage contribution to achieve a reversible six-electron-transfer redox reaction in a specific voltage range. The mechanism characterizations indicate that the nitrogen atoms on the porphyrin ring act as active sites to alternatively store both PF 6 − anions and Li + cations, and the charge storage process is a pseudocapacitive-dominated reaction. This observation will offer a new avenue for designing functionalized molecules for electrochemical energy-storage (EES) systems.
Atopic dermatitis (AD) is a common, chronic immuno-inflammatory skin disorder that commonly arises during childhood. Crisaborole ointment, 2%, is a nonsteroidal phosphodiesterase 4 inhibitor for the treatment of mild-to-moderate AD. This study aims to evaluate the efficacy and safety of crisaborole ointment, 2%, in pediatric Chinese and Japanese patients aged 2–17 years with mild-to-moderate AD. This post hoc analysis of a double-blind, vehicle-controlled, phase 3 study (CrisADe CLEAR; NCT04360187) evaluated the safety and efficacy of crisaborole in Chinese and Japanese patients aged ≥2 years with mild-to-moderate AD (involving ≥5% treatable body surface area). Patients were randomly assigned 2 : 1 to receive crisaborole or vehicle, respectively, twice-daily for 28 days. In this analysis, subgroups consisting of Chinese and Japanese patients aged 2–6 years, 2–11 years, and 12–17 years from the overall population were assessed. Efficacy endpoints included percent change from baseline in Eczema Area and Severity Index (EASI) total score at Day 29, improvement in Investigator’s Static Global Assessment (ISGA) score [score of 0 (clear) or 1 (almost clear)] at Day 29, success per ISGA (score of 0 or 1 with a ≥2-grade improvement from baseline) at Day 29, and change from baseline in Peak Pruritus Numerical Rating Scale (PP-NRS; used with permission from Regeneron Pharmaceuticals, Inc., and Sanofi) score at Week 4 (patients ≥12 years only). Safety was also assessed. Of 391 patients in the overall study, 93 were aged 2–6 years, 99 were aged 7–11 years, and 40 were aged 12–17 years. A greater reduction in percent change from baseline in EASI total score at Day 29 was shown in crisaborole- vs. vehicle-treated patients for patients aged 2–6 years and the overall population, with comparable reductions in other age subgroups (ClinicalTrials.gov, NCT04360187). Patients in the crisaborole group vs. the vehicle group had higher rates of ISGA improvement (age 2–6 subgroup) and success per ISGA (age 12–17 subgroup); comparable response rates were seen in other age subgroups (ClinicalTrials.gov, NCT04360187). Patients who received crisaborole showed a greater reduction vs. those who received vehicle in change from baseline in PP-NRS score at Week 4 in the overall population, with a comparable reduction seen in patients aged ≥12 years (ClinicalTrials.gov, NCT04360187). Crisaborole-treated patients in the overall population and each age subgroup had consistent but comparable improvement in all primary and key secondary efficacy endpoints. In patients aged 2–6 years, 55.4% and 62.2% of those who received crisaborole and vehicle, respectively, experienced all-cause treatment-emergent adverse events (TEAEs). All-cause TEAEs occurred in 52.2% and 34.4% of patients aged 7–11 years who received crisaborole and vehicle, respectively; in the aged 12–17 years subgroup, 36% and 40% of patients who received crisaborole and vehicle experienced all-cause TEAEs, respectively. The TEAEs occurring in ≥1% of patients across all subgroups included atopic dermatitis and treatment-related application site pain. Application site pain was most frequently reported in the face and neck. Most TEAEs were mild. There were no new safety findings. Crisaborole was effective and well tolerated in Chinese and Japanese patients aged 2–17 years with mild-to-moderate AD.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.